RT Journal Article
SR Electronic
T1 Co-circulation of Clade Ia and Ib monkeypox virus in Kinshasa Province, Democratic Republic of the Congo, July - August 2024
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.03.24312937
DO 10.1101/2024.09.03.24312937
A1 Wawina-Bokalanga, Tony
A1 Akil-Bandali, Prince
A1 Kinganda-Lusamaki, Eddy
A1 Lokilo, Emmanuel
A1 Jansen, Daan
A1 Amuri-Aziza, Adrienne
A1 Makangara-Cigolo, Jean-Claude
A1 Pukuta-Simbu, Elisabeth
A1 Ola-Mpumbe, Rilia
A1 Kacita, Cris
A1 Paku-Tshambu, Princesse
A1 Dantas, Pedro-Henrique L.F.
A1 Luakanda, Gradi
A1 Nkuba-Ndaye, Antoine
A1 Matondo, Meris
A1 Bulabula, Junior
A1 Hasivirwe Vakaniaki, Emmanuel
A1 O’Toole, Áine
A1 De Block, Tessa
A1 Ngandu, Christian
A1 Hoff, Nicole A.
A1 Low, Nicola
A1 Subissi, Lorenzo
A1 Merritt, Sydney
A1 Muyembe-Tamfum, Jean-Jacques
A1 Liesenborghs, Laurens
A1 Peeters, Martine
A1 Delaporte, Eric
A1 Kindrachuk, Jason
A1 Rimoin, Anne W.
A1 Ahuka-Mundeke, Steve
A1 Rambaut, Andrew
A1 Mwamba, Dieudonné
A1 Vercauteren, Koen
A1 Mbala-Kingebeni, Placide
YR 2024
UL http://medrxiv.org/content/early/2024/09/04/2024.09.03.24312937.abstract
AB Mpox cases have been reported in nearly all provinces of the Democratic Republic of the Congo as of August 2024. Monkeypox virus positive samples from Kinshasa, collected between July and mid-August 2024, were sequenced using a probe-based enrichment or optimized tiling sequencing protocol. With multiple introductions of both Clade Ia (7/12) and Ib (5/12), marking Kinshasa, and its Limete health zone specifically, as an area with co-circulation of both Clade I, a unique observation illustrating the growing complexity of Clade I mpox outbreaks in DRC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe project or effort depicted is sponsored in part by the Department of Defense Threat Reduction Agency (HDTRA1-21-1-0040). This work is also supported by the United States Department for Agriculture (USDA) Agriculture Research Service (ARS) (USDA ARS NACA number 20230048, grant number 58-3022-2-020). The content of the information does not necessarily reflect the position or the policy of the federal government, and no official endorsement should be inferred. The Africa Pathogen Genomics Initiative helped acquiring and maintaining the sequencer; Agence Francaise de Developpement through the AFROSCREEN project (grant agreement CZZ3209, coordinated by ANRS-MIE Maladies infectieuses emergentes in partnership with Institut de Recherche pour le Developpement (IRD) and Pasteur Institute) for laboratory support and PANAFPOX project funded by ANRS-MIE; Belgian Directorate-general for Development Cooperation and Humanitarian Aid (DGD), the Department of Economy, Science, and Innovation of the Flemish government, the Research Foundation - Flanders (FWO, grant number G096222 N to L.L.), and EDCTP Grant 101195465 (MBOTE-SK); the International Mpox Research Consortium (IMReC) through funding from the Canadian Institutes of Health Research and International Development Research Centre (grant no. MRR-184813); US NIAID/NIH grant number U01AI151799 through Center for Research in Emerging Infectious Disease-East and Central Africa (CREID-ECA). We acknowledge the support of the Wellcome Trust (Collaborators Award 206298/Z/17/Z, ARTIC network).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples were collected as part of national diagnostic and surveillance activities. Authorization for secondary use of the samples for research in this study was obtained from the Ethics Committee of Kinshasa School of Public Health (ESP-UNIKIN, Number ESP/CE/05/2023). The participants privacy was protected, and their data remained strictly anonymized.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.